Clinical importance of an elevated circulating chemerin level in incident dialysis patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 12, 2010, Pages 4017-4023

  Yamamoto, Tae ^a   Qureshi, Abdul Rashid ^a   Anderstam, Björn ^a   Heimbürger, Olof ^a   Bárány, Peter ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a   Axelsson, Jonas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adipokine; dyslipidaemia; end stage renal disease; insulin resistance; outcome

Indexed keywords

ADIPOCYTOKINE; APOLIPOPROTEIN B; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CHEMERIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY COMPOSITION; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIET RESTRICTION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEMODIALYSIS PATIENT; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUTRITIONAL ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

BIOLOGICAL MARKERS; CHEMOKINES; CHRONIC DISEASE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL DIALYSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 78649528499     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq329     Document Type: Article

References (31)

1. Axelsson J. The emerging biology of adipose tissue in chronic kidney disease: from fat to facts. Nephrol Dial Transplant 2008; 23: 3041-3046
2. Ramkumar N, Murtaugh MA, Cheung AK et al. Lack of synergistic effects of metabolic syndrome and plasma fibrinogen on coronary events and mortality in moderate CKD. Am J Kidney Dis 2007; 49: 356-364
3. Beddhu S, Nigwekar SU, Ma X et al. Associations of resting heart rate with insulin resistance, cardiovascular events and mortality in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2482-2488
4. Hajer GR, Van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008; 29: 2959-2971
5. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008; 10: 156-164
6. Axelsson J, Rashid Qureshi A, Suliman ME et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222-1229
7. Ikizler TA. Resolved: being fat is good for dialysis patients: the Godzilla effect: pro. J Am Soc Nephrol 2008; 19: 1059-1062
8. Stenvinkel P, HeimburgerO, Paultre Fet al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911
9. Sell H, Eckel J. Chemotactic cytokines, obesity and type 2 diabetes: in vivo and in vitro evidence for a possible causal correlation? Proc Nutr Soc 2009; 24: 1-7
10. Bozaoglu K, Bolton K, McMillan J et al. Chemerin is a novel adipo-kine associated with obesity and metabolic syndrome. Endocrinology 2007; 148: 4687-4694
11. Pfau D, Bachmann A, Lossner U et al. Serum levels of the adipokine chemerin in relation to renal function. Diab Care 2009; 33: 171-173
12. Detsky AS, McLaughlin JR, Baker JPet al. What is subjective global assessment of nutritional status? JPEN J Parenter Enteral Nutr 1987; 11: 8-13
13. Suliman ME, Anderstam B, Bergstrom J. Evidence of taurine depletion and accumulation of cysteinesulfinic acid in chronic dialysis patients. Kidney Int 1996; 50: 1713-1717
14. Fouque D, Kalantar-Zadeh K, Kopple J et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73: 391-398
15. Kilpatrick RD, McAllister CJ, Kovesdy CPet al. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007; 18: 293-303
16. Chmielewski M, Carrero JJ, Qureshi AR et al. Temporal discrepancies in the association between the apoB/apoA-I ratio and mortality in incident dialysis patients. J Intern Med 2009; 265: 708-716
17. Wittamer V, Franssen JD, Vulcano M et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med 2003; 198: 977-985
18. Zabel BA, Allen SJ, Kulig P et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005; 280: 34661-34666
19. Cash JL, Hart R, Russ A et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J Exp Med 2008; 205: 767-775
20. Takahashi M, Takahashi Y, Takahashi K et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008; 582: 573-578
21. Wang LY, Wei L, Yu HYet al. Relationship of serum chemerin to obesity and type 2 diabetes mellitus. Zhonghua Yi Xue Za Zhi 2009; 89: 235-238
22. Sell H, Laurencikiene J, Taube A et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009; 58: 2731-2740
23. Weigert J, Neumeier M, Wanninger J et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2009; 72: 342-348
24. Lehrke M, Becker A, Greif M et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009; 161: 339-344
25. Kaur J, Adya R, Tan BK et al. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2009; 391: 1762-1768
26. Suliman ME, Stenvinkel P, Qureshi AR et al. Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis 2004; 44: 455-465
27. Valli A, Carrero JJ, Qureshi AR et al. Elevated serum levels of S-adenosylhomocysteine, but not homocysteine, are associated with cardiovascular disease in stage 5 chronic kidney disease patients. Clin Chim Acta 2008; 395: 106-110
28. Giral P, Jacob N, Dourmap C et al. Elevated gamma-glutamyltransferase activity and perturbed thiol profile are associated with features of metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 587-593
29. Stejskal D, Karpisek M, Hanulova Z et al. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 217-221
30. Bozaoglu K, Segal D, Shields KA et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009; 94: 3085-3088
31. Ceccarini G, Flavell RR, Butelman ER et al. PET imaging of leptin biodistribution and metabolism in rodents and primates. Cell Metab 2009; 10: 148-159